Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Atirmociclib Formulations in Healthy Adults
NCT07130097Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Area under the Plasma Concentration-Time profile from time 0 to time of last quantifiable data point at 120 hours, Area under the Plasma Concentration-Time profile from time 0 extrapolated to infinite time at 120 hours and 1 more. Started Aug 2025; status: completed.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07130097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130097.